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background: Approximately 10% of patients (Pts) waiting for heart transplant (HTx) are sensitized. A smaller proportion of these pts are highly 
sensitized with Panel Reactive Antibody Screens (PRA) greater than 70%. These pts are reported to have greater risk for Antibody-Mediated Rejection 
(AMR) and greater risk for mortality following HTx. Furthermore, these pts are reported to have a longer waiting time because of the decreased pool 
of compatible donors. A new class of medications include the proteasome inhibitors such as Bortezomib. This is the first in its class of medications 
to directly attack plasma cells thereby decreasing antibody production. There has been contention as to the efficacy and safety of this medication 
to reduce circulating antibodies (Abs) in pts awaiting HTx. Therefore we sought to review our experience with use of Bortezomib in lowering antibody 
load in our highly sensitized pt population.
Methods: Between 2009 and 2012 we reviewed 14 pts awaiting HTx who were highly sensitized with PRA > 70% and underwent Bortezomib 
desensitization therapy consisted of 4 doses at 1.3 mg/m2 along with 2 daily plasmapheresis sessions prior to each Bortezomib dose. We reviewed 
Abs levels before Bortezomib and after therapy to assess for a decrease for Abs response. We also assessed for adverse effects including infections 
that occurred during therapy or within 30 days after cessation of the therapy.
results: The average PRA prior to Bortezomib therapy was 81 ± 10% for HLA class I Abs and 76 ± 16% for HLA class II Abs. After treatment 
the average PRA was reduced to 51 ± 35% for HLA class I Abs and 68 ± 16% for HLA class II Abs (p < 0.01 for both groups). 11 episodes of 
complications were seen in 8 Bortezomib desensitized pts which included the following: Neuropathy (n = 3), Infection (n = 4), and Bone Marrow 
Suppression (n = 4). Post-transplant freedom from 1-year Acute Cellular Rejection was 92.9% and freedom from 1-year AMR was 85.7%.
conclusions: Bortezomib for highly sensitized pts appears to be effective to reduce circulating Abs with acceptable site affects and post-
transplant outcome.
